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Abstract
To control the rate of release of methylprednisolone (MP) in lysosomes, new dextran-MP conjugates
with peptide linkers were synthesized and characterized. Methylprednisolone succinate (MPS) was
attached to dextran 25 kDa using linkers with 1–5 Gly residues. The release characteristics of the
conjugates in pH 4.0 and 7.4 buffers, blood, liver lysosomes, and various lysosomal proteinases were
determined using a size-exclusion and/or a newly-developed reversed-phase HPLC method capable
of simultaneous quantitation of MP, MPS, and all five possible MPS-peptidyl intermediates. We
synthesized conjugates with ≥ 90% purity and 6.9–9.5% (w/w) degree of MP substitution. The
conjugates were stable at pH 4.0, but released MP and intact MPS-peptidyl intermediates in the pH
7.4 buffer and rat blood, with faster degradation rates for longer linkers. Rat lysosomal fractions
degraded the conjugates to MP and all the possible intermediates also at a rate directly proportional
to the length of the peptide. Whereas the degradation of the conjugates by cysteine peptidases (papain
or cathepsin B) was relatively substantial, no degradation was observed in the presence of aspartic
(cathepsin D) or serine (trypsin) proteinases, which do not cleave peptide bonds with Gly. These
newly-developed dextran conjugates of MP show promise for controlled delivery of MP in
lysosomes.
Keywords
controlled delivery; controlled release; targeted drug delivery; prodrugs; synthesis; HPLC; stability;
linker; spacer
INTRODUCTION
Methylprednisolone (MP) is a glucocorticoid with well-defined anti-inflammatory and
immunosuppressive effects.1 In liver transplantation, MP is used as a first line therapy in the
treatment of acute rejection.2,3 For this purpose, large intravenous doses of the drug (~ 1 g/
day) are administered as pulse therapy, usually over 3–5 days. However, this regimen has been
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associated with significant life-threatening toxicities.2,4 Therefore, a targeted delivery of MP
to the liver in liver-transplanted patients may afford administration of smaller doses, resulting
in prolonged local effects in the liver, with less toxicity to other organs.
A variety of approaches, such as the use of macromolecular carriers, have been explored to
selectively deliver drugs to their target site.5,6 Among various macromolecules, dextrans are
one of the most extensively investigated carriers because they are water-soluble and
biodegradable natural polysaccharides, which have been used clinically as plasma volume
expanders for several decades.7,8 Additionally, dextrans are available commercially as
different molecular weights and have numerous hydroxyl groups that can be easily conjugated
to the parent drug. Therefore, they have been investigated as macromolecular carriers for the
delivery of a number of therapeutic agents, such as anticancer and steroidal and non-steroidal
drugs.8
Recently, we conjugated MP to dextran with a Mw of 70 kDa, using succinic acid as a linker,
and investigated its hydrolysis kinetics,9 pharmacokinetics,10 and pharmacodynamics11,12
in rats. It was demonstrated that the conjugate would selectively accumulate and gradually
release MP in the liver and spleen, resulting in a more intense and sustained immunosuppressive
activity in these organs, compared with administration of an equal dose of the parent drug.
Additionally, studies in a rat liver transplantation model indicated that the conjugate is superior
to MP for prevention of rejection of allograft in this model.13 However, despite very high
accumulation of the conjugate in the liver and spleen, the release of MP from the conjugate
was slow and incomplete.11,12 The conjugate:MP concentration ratios in the liver and spleen
tissues were relatively large and increased with time, resulting in the disappearance of
immunosuppressive activity at later time points despite the presence of large concentrations
of the conjugate in these tissues.11,12 Therefore, the present study was designed to develop
and test the second generation dextran prodrugs of MP containing various peptides as linkers
between dextran and MP succinate (MPS). Previous studies have shown that peptide linkers
of various length and amino acid type and sequence may be degraded at different rates by
lysosomal enzymes.14–16 Therefore, the hypothesis of this investigation was that the rate of
regeneration of MP from its dextran prodrug can be controlled using different peptide linkers.
Hydrolysis of MPS-peptide-dextran prodrugs would potentially lead to the formation of MP,
MPS, and MPS-peptidyl intermediates. Therefore, for stability, purity, and release
investigations, it is desirable to quantitate all possible components, including intermediates, in
the sample.
In this article, synthesis and characterization of MPS-peptide-dextran prodrugs (DMP) with
five different peptides are described. Additionally, a new HPLC method for simultaneous
quantitation of MP, MPS, and five MPS-peptidyl intermediates is developed and validated.
The assay is used for the determination of the in vitro release profiles of all the possible
intermediates from prodrugs in the presence of various peptidases, rat liver lysosomes, or
buffers with different pH values. The stability of the conjugates in rat blood was also quantitated
using size-exclusion chromatography.
EXPERIMENTAL SECTION
Chemicals
Dextran with an average Mw of 23,500 was obtained from Dextran Products Ltd. (Scarborouh,
Ontario, Canada). 6α-Methylprednisolone (MP) was purchased from Steraloids (Newport, RI,
USA). Fmoc-Gly-Wang resin, coupling reagents, and Fmoc-amino acid building blocks,
Fmoc-Gly-OH and Fmoc-methyl Gly (mGly)-OH, were purchased from Novabiochem (San
Diego, CA). Papain from papaya latex (33 U/mg), cathepsin B from bovine spleen (24 U/mg),
cathepsin D from bovine spleen (5 U/mg), trypsin from bovine pancreas (10 KU/mg), rat liver
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lysosome isolation kit, and acid phosphatase assay kit were purchased from Sigma (St. Louis,
MO). For chromatography HPLC grade acetonitrile (EMD) was obtained from VWR Scientific
(Minneapolis, MN, USA). All other reagents were analytical grade and obtained through
commercial sources.
Animals
Adult, male Sprague-Dawley rats were used as blood donors and for the preparation of liver
lysosomal fractions described later. All the procedures involving animals in this study were
consistent with the “Principles of Laboratory Animal Care” (NIH publication Vol. 25, No. 28,
revised 1996) and approved by the Texas Tech University Health Sciences Center Institutional
Animal Care and Use Committee.
Synthesis and Characterization of Dextran Prodrugs of Methylprednisolone (DMP)
The chemical structures of final products were characterized by nuclear magnetic resonance
spectrometry (1H NMR, 13C NMR) determined on a Bruker NMR spectrometer (400
MHz). 13C NMR spectra are fully decoupled. Chemical shifts are reported in parts per millions
(ppm). The chemical structures of final products were confirmed by a high-resolution PE
Biosystems Mariner API time-of-flight electrospray mass spectrometer.
Synthesis of MP Succinate (MPS)—4-Dimethylaminopyridine (DMAP, 100 mg, 0.82
mmol) and succinic anhydride (290 mg, 2.90 mmol) were added to a solution of MP (1.08 g,
1.45 mmol) in dry pyridine (15.0 mL). The reaction mixture was stirred at room temperature
overnight. After completion of the reaction, the solvent was evaporated under reduced pressure
and the crude compound was purified by column chromatography over silica gel using
dichloromethane/methanol as the eluents to yield MPS (1.35 g, 98.5%).
1H NMR (400 MHz, DMSO-d6, δ ppm) 12.25 (s, 1H,), 7.32 (d, J = 10.2 Hz, 1H), 6.18 (d, J =
10.2 Hz, 1H), 5.82 (s, 1H), 5.40 (s, 1H), 5.07 (d, J = 17.6 Hz, 1H), 4.76 (d, J = 17.6 Hz, 1H),
4.28 (s, 1H), 2.63–2.60 (m, 3H), 2.51–2.48 (m, 3H), 2.10–2.01 (m, 2H), 1.87 (d, J = 10.4 Hz,
1H), 1.66–1.57 (m, 3H), 1.45–1.41 (m, 1H) 1.38 (s, 3H), 1.35–1.28 (m, 1H), 1.04 (d, J = 6.1
Hz, 3H), 0.86–0.83 (m, 1H), 0.78 (s, 3H), 0.75–0.66 (m, 1H). 13C NMR (100 MHz, DMSO-
d6, δ ppm) 206.00, 185.97, 174.25, 174.10, 172.49, 158.08, 127.53, 119.60, 89.04, 69.11, 68.49,
56.72, 51.79, 47.88, 44.84, 43.72, 33.94, 33.28, 31.60, 29.47, 29.27, 24.30, 22.17, 18.46, 17.38;
HR-MS (ESI-TOF) (m/z): C26H34O8 calcd, 474.2254; found 497.3423 [M + Na + H]+.
Synthesis of MPS-Peptide Conjugates—Synthesized MPS-peptides contained mGly
(MPS-mG-OH), mGly-Gly (MPS-mGG-OH), mGly-Gly-Gly (MPS-mGGG-OH), mGly-Gly-
Gly-Gly (MPS-mGGGG-OH), or mGly-Gly-Gly-Gly-Gly (MPS-mGGGGG-OH).
Additionally, two MPS-peptides without mGly (MPS-GG-OH and MPS-GGGG-OH) were
synthesized for comparative purposes. As a representative example, the synthesis of MPS-
mGGGGG-OH is given here (Scheme 1). The peptide was assembled on Fmoc-Gly-Wang
resin (600 mg, 0.66 mmol/g) by Fmoc solid phase peptide synthesis strategy on a PS3
automated peptide synthesizer (Rainin Instrument Co., Oakland, CA) at room temperature
using Fmoc protected amino acids [Fmoc-Gly-OH (C+1), Fmoc-Gly-OH (C+2), Fmoc-Gly-
OH (C+3), Fmoc-mGly-OH (C+4)] (1.58 mmol) and MPS (1.58 mmol). 2-(1H-
Benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU) (1.58 mmol)
and N-methylmorpholine (NMM) (1.58 mmol) in N,N-dimethylformamide (DMF) were used
as coupling and activating reagents, respectively. Fmoc deprotection at each step was carried
out using piperidine in DMF (20%). MPS-mGGGGG-OH was cleaved from the resin by a
mixture of TFA/anisole/water (95:2.5:2.5), precipitated by the addition of cold diethyl ether
(Et2O). The crude peptide conjugates were purified by HPLC (Shimadzu LC-8A preparative
liquid chromatograph; Shimadzu fraction collector 10A) on a Phenomenex® Prodigy 10μm
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ODS reversed-phase column. All MPS-peptide conjugates were separated by eluting the crude
peptide at 4.0 mL/min using a gradient of 0–100% acetonitrile (0.1% TFA) and water (0.1%
TFA) over 60 min and were lyophilized.
MPS-mGGGGG-OH: 1H NMR (400 MHz, DMSO-d6, δ ppm) 8.21–8.12 (m, 4H), 7.32 (d, J
= 10.1 Hz, 1H), 6.18 (d, J = 10.1, 1H), 5.81 (s, 1H), 5.05 (dd, J = 17.6 Hz, 3.8 Hz, 1H), 4.76
(d, J = 17.6 Hz, 2H), 4.28 (s, 1H), 4.05 (s, 1H), 3.95 (s, 1H), 3.83–3.68 (m, 8H), 2.89 (s, 1H),
2.79 (s, 1H), 2.73 (s, 1H), 2.64–2.45 (m, 3H), 2.10–2.01 (m, 2H), 1.88 (d, J = 10.7 Hz, 1H),
1.66–1.61 (m, 3H), 1.45–1.30 (m, 5H), 1.04 (d, J = 6.2, 3H), 0.86–0.66 (m, 5H); 13C NMR
(100 MHz, DMSO-d6, δ ppm) 205.28, 185.15, 173.48, 172.03, 171.33, 171.13, 169.24, 169.10,
168.86, 168.55, 157.27, 126.67, 118.75, 88.58, 68.28, 67.52, 55.91, 50.96, 50.35, 47.04, 44.01,
42.90, 42.02, 41.73, 40.57, 40.11, 35.98, 34.34, 33.07, 32.44, 30.77, 28.56, 27.54, 23.45, 21.32,
17.60,16.51; HR-MS (ESI-TOF) (m/z): C37H51N5O13 calcd, 773.3483; found 773.1624
[M]+, 1543.3510 [2M – 3H]+.
1H NMR, 13C NMR, and HR-MS (ESI-TOF) (m/z) for other MPS-peptide conjugates are
provided in Supporting Information.
Synthesis of MPS-Peptide-Dextran (DMP) Conjugates—The following conjugates
were synthesized: MPS-mG-Dex, MPS-mGG-Dex, MPS-mGGG-Dex, MPS-mGGGG-Dex,
and MPS-mGGGGG-Dex. Additionally, in preliminary studies, MPS-GG-Dex and MPS-
GGGG-Dex were synthesized. As a representative example, the synthesis of MPS-mGGGGG-
Dex is given here (Scheme 1). To the stirring solution of MPS-mGGGGG-OH (350 mg),
dextran (200 mg), and 4-dimethylaminopyridine (DMAP) (30 mg. 0.25 mmol) in dry DMSO
(3.0 mL) in a dry round bottom flask under nitrogen atmosphere was added N,N-
diisopropylethylamine (DIPEA, 200 μL, 1.21 mmol) followed by N,N′-
diisopropylcarbodiimide (DIC, 60 μL, 0.39 mmol). The reaction mixture was stirred at 40°C
for 48 h and poured into a cold ethanol (30 mL). The precipitate was centrifuged and washed
twice with cold ethanol:diethyl ether (50:50, v/v), and finally with cold ethanol:acetonitrile
(70:30, v/v). The solid was centrifuged and dried under vacuum to give MPS-mGGGGG-Dex
conjugate.
Further Characterization of the Conjugates
Purities of the powders were determined using the size-exclusion chromatographic (SEC)
method described below. The degree of substitution of MP in various conjugates was
determined by hydrolysis of the conjugate under basic conditions. To 1.0 mg of the conjugate
were added 1 mL of 0.1 N NaOH and 0.6 mL of methanol. After leaving the mixture at room
temperature for 5 min, 100 μL of the sample was micropipetted into a microcentrifuge tube
containing 100 μL of 0.1 M HCl. An aliquot (50 μL) was then injected into a reversed-phase
HPLC method described below.
Degradation/Hydrolysis of Conjugates
Chemical Hydrolysis in Buffers—Hydrolysis of various DMP conjugates at a
concentration equivalent to 100 μg/mL MP was studied at 37°C in pH 7.4 (100 mM phosphate
buffer) and 4.0 (50 mM acetate buffer), simulating the physiological and lysosomal pH,
respectively. Samples (100 μL, n = 3) were taken at different times after incubations (0–12 h)
into siliconized microcentrifuge tubes, and processed as described below before analysis by
both SEC and reversed-phase assays for quantitation of the intact conjugates and released
intermediates, respectively.
Blood Hydrolysis—Blood was obtained from six anesthetized (ketamine:xylazine; 80:8 mg/
kg, im), untreated rats by cardiac puncture. Approximately 4 IU of heparin was added to each
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mL of blood to prevent coagulation. Immediately after the collection of blood, DMP conjugates
(in isotonic phosphate buffer at pH 7.4) were added to produce a blood concentration of 10
μg/mL (MP equivalent). After mixing blood with the conjugates, samples were incubated at
37°C. Preliminary studies indicated that incubation of rat blood at 37°C for longer than 2 h
might be associated with a progressive decrease in pH, which could affect the degree of
hydrolysis. Therefore, we limited our blood studies to 6 h and kept the pH within 7.35–7.45,
by addition of small total volumes of 5–10 μl of isotonic sodium bicarbonate solution (1.5%,
w/v) to the incubation media (~4 mL). Samples were then taken at 0, 1, 3, and 6 h and
immediately centrifuged to separate plasma. Plasma samples were then processed as described
below before analysis of the intact conjugates by the SEC method.
Hydrolysis in the Presence of Peptidases—Hydrolysis of DMP conjugates in the
presence of various types of peptidases was studied at peptidase concentrations of
approximately 8 μM. The tested peptidases included cysteine (papain and cathepsin B), aspartic
(cathepsin D), and serine (trypsin) proteinases. The latter two peptidases were included as
negative controls because, based on their substrate specificity,17,18 they are not expected to
cleave peptide bonds with Gly. DMP conjugates at a concentration equivalent to 100 μg/mL
MP were incubated in 50 mM acetate buffer (pH 4), 5 mM reduced glutathione, and respective
peptidases at 37°C. In the case of trypsin, CaCl2 at a final concentration of 10 mM was also
added. Samples were then taken at 0, 3, 6, 12, 24, and 48 h and treated as described below
before injection into the reversed-phase HPLC.
Liver Lysosome Hydrolysis—Crude lysosomal fractions were prepared from the liver of
untreated rats according to the procedure described in the lysosome isolation kit. Briefly, rats
(n = 3) were anesthetized by an im injection of ketamine:xylazine (80:8 mg/kg), and after
cannulation of the portal vein, the livers were perfused with ice-cold PBS and removed. The
livers were then homogenized in 4 volumes of the extraction buffer, followed by differential
centrifugation for isolating the lysosomal fraction. The protein concentrations in lysosomal
preparations were determined by Bio-Rad protein assay (Bio-Rad, Herecules, CA, USA). The
activity of acid phosphatase, a lysosomal marker, in the preparation was tested using a
commercial kit (Sigma). The specific enzyme activity in the lysosomal fraction was >9-fold
that in the liver homogenate.
For lysosomal hydrolysis studies, DMP conjugates (100 μg/mL, MP equivalent) were
incubated at 37°C in 50 mM acetate buffer (pH 4.0) in the presence of 5 mM reduced glutathione
and 5 mg/mL lysosomal protein. Samples (100 μL) were then taken at 0, 3, 6, 12, 24, and 48
h and treated as described below before reversed-phase HPLC analysis.
Sample Preparation
Except for blood, 100 μL of methanol and 20 μL of 10% (v/v) acetic acid were added to all
the samples (100 μL) immediately after their collection to stop further hydrolysis. Preliminary
studies indicated that the treatment of samples with acetic acid and methanol renders them
stable for at least 24 h at room temperature. Addition of methanol and acetic acid also caused
precipitation of proteins in the peptidase and lysosomal studies. After vortex mixing (5 sec)
and centrifugation (10,000 rpm for 5 min), the resultant supernatants were transferred to
autosampler inserts and a 50 or 150 μL aliquot was injected into the SEC or reversed-phase
HPLC methods, respectively, described below. All the samples were analyzed within 10 h after
collection.
Plasma samples were only analyzed by SEC method because endogenous peaks in plasma
interfered with the reversed-phase assay of the intermediates. Immediately after collection, 20
μL of 10% acetic acid was added to 100 μL of plasma, and the samples were stored at −80°C
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until analysis within 24 h. To precipitate proteins before HPLC analysis, 80 μL of cold methanol
and 20 μL of 20% (v/v) perchloric acid (70%) were added to the samples. After a brief vortex
mixing and centrifugation, 150 μL of the supernatant was transferred to a new microcentrifuge
and 100 μL of HPLC water and 75 μL of 0.5 M phosphate buffer (pH 7.0) were added, and a
100 μL aliquot was subjected to the SEC method described below.
Analytical Methods
The concentrations of MP, MPS, and MPS-peptidyl intermediates, including MPS-mG-OH,
MPS-mGG-OH, MPS-mGGG-OH, MPS-mGGGG-OH, and MPS-mGGGGG-OH, in the
samples were determined by a reversed-phase HPLC method developed and validated in our
laboratory. The samples were analyzed at ambient temperature using a 25 cm × 4.6 mm C18
(5 μm) column (Partisil ODS-3, Whatman, Florham Park, NJ), preceded by a guard column
packed with spherical C18 silica gel (20–45 μm). The isocratic mobile phase consisted of 0.1
M phosphate buffer (pH 4.6):acetonitrile (73:27), which was pumped at a flow rate of 1 mL/
min.
The validity of the assay was investigated by determination of the accuracy and precision of
the assay based on the reported guidelines.19 The inter-run validity was determined by
analyzing five replicates of quality control samples at each concentration of 0.5, 5, and 100
μg/mL against the calibration standards in the range of 0.5–100 μg/mL on different days.
Calibration standards were prepared in lysosomal matrix after deactivation of the enzymes at
100°C for 60 minutes. The accuracy and precision values were then calculated by percent errors
and CVs, respectively. To determine the recovery of the analytes from lysosomes after protein
precipitation, lysosomal samples (n = 3) containing 5 or 100 μg/mL of all the five MPS-peptidyl
linkers, MP, and MPS were analyzed using the above assay. The peak areas obtained from
these samples were then compared with those containing equivalent concentrations of the
analytes in HPLC water.
Concentrations of the intact prodrugs were analyzed using a slightly modified size-exclusion
chromatographic assay reported before for the assay of MP-succinate-dextran conjugates.20
Briefly, conjugates were separated from impurities or other interfering peaks using a 30 cm ×
7.8 mm analytical, gel chromatography column (PolySep-GFC 3000; Phenomenex, Torrance,
CA) at ambient temperature. The mobile phase consisted of KH2PO4 (10 mM) and acetonitrile
(65:35) and was pumped at a flow rate of 1.0 mL/min.
The HPLC instrument (Waters, Milford, MA, USA) consisted of a 515 pump, a 717
autosampler, and a 997 photodiode array detector, operated in the range of 245–255 nm. The
chromatographic data was managed using Empower software (Waters).
Data Analysis
The time-dependent decline in the conjugate concentration after incubation in various media
was fitted using a first-order kinetic model, and the degradation half life was estimated from
the slope of the fitted lines. The statistical differences among various conjugates were analyzed
using ANOVA with post-hoc Scheffe’s F test. All tests were performed at a significance level
(α) of 0.05. Data are presented as mean ± SD.
RESULTS
Synthesis and Characterization
MP was conjugated to dextran using peptide linkers in three major steps: (i) synthesis of 5′-
O-succinate ester of the drug (MPS), (ii) the reaction of MPS with resin-bound peptides and
cleavage, and (iii) the reaction of MPS-peptide conjugates with dextran (Scheme 1). MP was
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converted to MPS in the presence of pyridine and succinic anhydride. MPS was conjugated to
dextran through the peptide linkers. In general, all peptides were assembled on Fmoc-Gly-
Wang resin by the solid-phase synthesis strategy employing Fmoc-based chemistry and Fmoc-
L-amino acid building blocks (i.e., Fmoc-Gly-OH, Fmoc-mGly-OH). After the Fmoc
deprotection with piperidine, the free N-terminal of the peptides was conjugated with MPS to
afford polymer-bound MPS-peptide conjugates. MPS-mG-OH was synthesized by anchoring
Fmoc-mG-OH on Wang resin, followed by MPS. Acidic cleavage of the conjugates from Wang
resin, followed by reaction with dextran in the presence of DIC and DIEA afforded MPS-mG-
dextran, MPS-mGG-dextran, MPS-mGGG-dextran, MPS-mGGGG-dextran, MPS-
mGGGGG-dextran, MPS-GG-dextran, and MPS-GGGG-dextran (Scheme 1). The reaction
between dextran and MPS-peptide can potentially occur via any of its three hydroxyl groups
present in each glucose molecule (Scheme 1). However, the exact site of substitution was not
determined in this study.
The degree of substitution and purity of different conjugates used in this study are reported in
Table 1. The purity, determined by SEC of the intact conjugate, was ≥90% for all the
conjugates. The degrees of MP substitution were also very close for all the conjugates and
ranged from 6.9% to 9.5% (w/w). For consistency, batches of conjugates that had degrees of
substitution higher than 10% or lower than 6.5% were not used in this study.
HPLC Analysis of Intermediates
Chromatograms of a blank lysosomal sample, a standard lysosomal sample containing 5 μg/
mL of MP, MPS, MPS-mG-OH, MPS-mGG-OH, MPS-mGGG-OH, MPS-mGGGG-OH, and
MPS-mGGGGG-OH, and a lysosomal sample taken 48 h after incubation (37°C) with MPS-
mGGGGG-Dex (100 μg/mL of MP equivalent) are depicted in Figure 1. Under the stated
chromatographic conditions all the 7 analytes of interest were separated from each other with
retention times of 14, 15, 16, 18, 20, 25, and 47 min for MPS-mGGGGG-OH, MPS-mGGGG-
OH, MPS-mGGG-OH, MPS-mGG-OH, MPS-mG-OH, MP, and MPS, respectively (Fig. 1).
Five calibration curves were used to determine the inter-run validation of the assay, the results
of which are presented in Table 2. The responses of the detector to analytes were linear
(r2≥0.99) over the studied range of 0.5 – 100 μg/mL for all the components. The accuracy of
the assay was demonstrated by error values of <14 % for all the components at all the
concentrations, including the lower limit of quantitation of 0.5 μg/mL. Additionally, the
precision of the assay was demonstrated by the CV values of ≤12 %.
The recoveries of all the components from the lysosomal samples were almost complete with
efficiencies ranging from 94 to 104% and 96 to 102% at the lowest (0.5 μg/mL) and highest
(100 μg/mL) concentrations, respectively.
Hydrolysis of DMP Conjugates in Buffer
The concentrations of DMP conjugates as a function of incubation (37°C) time in pH 7.4 buffer,
measured using the SEC assay, are depicted in Fig. 2, and the corresponding degradation half
lives are reported in Table 3. The degradation of DMP conjugates in pH 7.4 buffer was
dependent on the length of the linker (p < 0.05, ANOVA); an increase in the length of linker
from one (MPS-mG-Dex) to five (MPS-mGGGGG-Dex) amino acids decreased the
degradation half life from 10.7 ± 0.1 h to 4.27 ± 0.02 h (Fig. 2 and Table 3). However, except
for MPS-mG-Dex, which showed a degradation half life twice as long, the half lives were close
for all the other linkers (Table 3). Consistent with the half life values, the concentrations of the
DMP conjugates remaining after 12 h of incubation at pH 7.4 and 37°C ranged from 15%
(MPS-mGGGGG-Dex) to 46% (MPS-mG-Dex) (Fig. 2).
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Time courses of the release of MP and its peptidyl intermediates at pH 7.4, measured using the
reversed-phase assay, are demonstrated in Figure 3. For all the conjugates, the released moieties
were only MP and the MPS attached to the intact peptidyl spacer, indicating chemical
hydrolysis of ester bonds only (Scheme 1). The total concentration of MP released, relative to
the initial conjugate concentration, during 12 h of incubation at pH 7.4 was substantial, ranging
from 38% for MPS-mG-Dex to 66% for MPS-mGGGG-Dex (Fig. 3). Although the
concentrations of total MP (MP plus MPS-peptidyl derivatives) varied with the length of the
linker, those of the free MP seemed not much different among different conjugates (Fig. 3).
In contrast to the relatively significant degradation of DMP conjugates at pH 7.4 (Fig. 3), no
discernable decline in the concentrations of the conjugates was observed in the SEC assay after
incubation at pH 4.0 (data not shown). Additionally, only minor amounts (≤3%) of the released
products of DMP were seen at pH 4.0 using the reversed-phase assay. However, in agreement
with the release patterns at pH 7.4 (Fig. 3), only MP and MPS attached to the intact linker were
observed for all the conjugates.
Hydrolysis of DMP in Blood
The results of degradation of DMP conjugates in blood, based on measurements of the parent
conjugates, are presented in Fig. 4 and Table 3. The degradation of the conjugates in blood
was dependent on the length of the peptide linker, with MPS-mG-Dex and MPS-mGGGGG-
Dex exhibiting the slowest and fastest degradation, respectively (Fig. 4 and Table 3). However,
the differences in the degradation half lives among the conjugates with 2–4 amino acids were
not significant (Fig. 4 and Table 3). The conjugate concentrations remaining at 6 h and
corresponding half lives ranged from 38 to 81% (Fig. 4) and 4.67 to 24.5 h (Table 3),
respectively. The degradation half lives of MPS-mG-Dex and MPS-mGGG-Dex in blood were
significantly longer than their corresponding values at pH 7.4 buffer (Table 3).
Hydrolysis of DMP by Peptidases
Papain—Papain-mediated release of MP and MPS-peptidyl intermediates is shown in Fig. 5.
Except for MPS-mG-OH, all the other possible MPS-peptidyl intermediates were observed in
relatively high concentrations for all the conjugates (Fig. 5). The total MP released from the
conjugates during 48 h of incubation with papain ranged from 31% for MPS-mG-Dex to 71%
for MPS-mGGGGG-Dex (Figure 5). Overall, the % total MP release appeared to be dependent
on the length of the peptide linker, whereas the free MP release appeared to be similar for all
the conjugates (Fig. 5).
Cathepsin-B—Cathepsin-B-mediated degradation of the dextran conjugates of MP is
demonstrated in Fig. 6. With the exception of appearance of cathepsin-B-mediated MPS-mG-
OH intermediate for most conjugates, the qualitative pattern of conjugate hydrolysis by
cathepsin-B (Fig. 6) was similar to that observed for papain (Fig. 5). However, the % total MP
release (5–17%, Fig. 6f) by cathepsin B was much lower than that seen by papain incubation
(Fig. 5f). A decrease in the length of the linker caused a progressive decrease in the cathepsin-
B-mediated MP and MPS-peptidyl intermediate release (Fig. 6f).
Cathepsin-D and Trypsin—To understand the enzyme specificity for the degradation of
the conjugate, we included cathepsin D, as an aspartyl proteinase, and trypsin, as a serine
proteinase, in our studies as negative controls. As expected, the rate of release of free MP and
MPS-peptidyl intermediates was very slow and negligible with both enzymes (data not shown).
Hydrolysis of DMP in Liver Lysosomes
The hydrolysis patterns of conjugates in the presence of lysosomal fraction are demonstrated
in Fig. 7. Lysosomal degradation caused release of free MP and all the possible MPS-peptidyl
Penugonda et al. Page 8
J Pharm Sci. Author manuscript; available in PMC 2008 July 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
intermediates, including relatively high concentrations of MPS-mG-OH. However, for most
conjugates, MP was by far the most abundant released moiety (Fig. 7). The total amount of
MP and MPS-peptidyl intermediates released in the presence of lysosomes ranged from 3%
(MPS-mG-Dex) to 11% (MPS-mGGGGG-Dex) (Fig. 7f). An increase in the peptide link
caused an increase in the release of MP and/or its peptidyl intermediates, although hydrolysis
of MPS-mGG-Dex deviated from this pattern (Fig. 7f).
DISCUSSION
Dextran macromolecular prodrugs are usually synthesized by covalent attachment of drugs,
directly or through a spacer arm, to the dextran polymer.7,8 The drug is then released in vivo
by hydrolytic and/or enzymatic cleavage of the linking bond. Therefore, the rate of the drug
release is dependent on the nature of the linking bond and the type and length of the spacer
group. Our previous studies on a 70 kDa dextran prodrug of MP with a succinate linker,
although promising, demonstrated some shortcomings. First, the conjugate showed a slow and
incomplete release of MP both in vitro9 and in vivo,11,12 reducing the potential duration and
intensity of action of the conjugate. Additionally, in vivo pharmacokinetic studies indicated
some degree of nonlinearity in the elimination of the conjugate, most likely due to the large
Mw of the dextran carrier.21 This study was therefore undertaken to synthesize new dextran
conjugates of MP with necessary modifications that would be devoid of the above
shortcomings.
Our previous works on dextran carriers have shown that although liver accumulation of dextran
70 kDa is modestly higher than that of dextran 20 kDa, the lower Mw dextran is expected to
follow linear pharmacokinetics because of more involvement of a linear renal clearance in its
elimination.22,23 Additionally, peptide linkers are expected to be superior to the succinate
linker because the rate of release of drugs from macromolecular prodrugs with such linkers
may be controlled by the length, type, and sequence of amino acids.15,16 Therefore,
modifications incorporated in the synthesis of the new conjugates included the use of dextran
~25 kDa, instead of 70 kDa, as a carrier and peptides of various lengths, instead of succinic
acid, as linkers between MP and dextran.
Our initial attempts at synthesis of MPS-peptide-dextran conjugates using Gly-Gly or Gly-
Gly-Gly-Gly as linkers resulted in conjugates with very low (<1%) degrees of MP substitution,
which were very unstable in aqueous solutions (data not shown). Changes in the synthetic
procedures such as increasing the length of reactions and/or changing the reagents or activation
methods did not improve these shortcomings. The rapid hydrolysis of these conjugates is
consistent with a recent report24 in which authors demonstrated cyclization of a prednisolone
succinate β-cyclodextrin amide conjugate, resulting in a rapid release of prednisolone.
Although the release of prednisolone from prednisolone-21-hemisuccinate was very slow with
a half life of 69 h at pH 7.0 and 37°C, the hydrolysis of prednisolone 21-hemisuccinate-β-
cyclodextrin amide conjugate, even at a lower temperature of 25°C, was very fast with a half
life of 6.5 min in the same buffer. The authors attributed this behavior to an intramolecular
nucleophilic catalysis of the amide group, which occurs in the alkaline region. The same
intramolecular rearrangement could theoretically be responsible for the fast release of MP from
our initial conjugates with Gly-Gly or Gly-Gly-Gly-Gly linkers, resulting in a low degree of
substitution. If true, incorporation of N-methyl glycine, instead of glycine, at the N-terminal
of peptide linker is expected to prevent this undesired cyclization. Indeed, when we used this
latter approach (Scheme 1), we were able to obtain conjugates with relatively high degree of
MP substitution (Table 3) with improved stability in aqueous solutions (Fig. 2).
Simultaneous quantitation of hydrolyzed intermediates of MP, including five MPS-peptidyl
intermediates, and MP and MPS required for stability and release studies was challenging.
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Previously, we reported a method for the simultaneous measurement of MP and MPS,25 which
could not be adapted to separate all seven analytes of interest in the current study. Because of
the succinyl moiety, the retention times of MPS and all the MPS-peptidyl intermediates are
sensitive to both the organic modifier and pH of the mobile phase, whereas the retention time
of MP is pH-independent. We took advantage of these characteristics to resolve all seven
analytes of interest within a run time of <50 min (Fig. 1).
The hydrolysis of DMP conjugates in pH 7.4 buffer at 37°C to release only MP and intact
MPS-peptide linker (Fig. 3) indicates chemical hydrolysis of the two ester bonds in the structure
of the conjugates (Scheme 1). Whereas hydrolysis of the ester bond between dextran hydroxyl
groups and the C-terminal of the linker amino acid would result in the release of intact MPS-
peptide linker, hydrolysis of the ester bond between MP and succinic acid would yield free
MP. Free MP may also be released indirectly from the regenerated MPS-peptide linker. The
linker length-dependent degradation half life of conjugates at pH 7.4 (Fig. 2, Table 3) suggests
that the ester bonds in the conjugates with longer linkers are more prone to hydrolysis, probably
due to the electronic effect of the linker. Longer linkers have more electron withdrawing groups
because of the presence of multiple amide bonds. Therefore, it is possible that the ester moieties
of the conjugates with longer linkers become more polarized with the presence of partially
positive and negative charges on the carbon and oxygen, respectively, rendering them more
susceptible to nucleophilic attack by water.
It is commonly assumed that the degradation of prodrugs may be faster in blood, compared
with pH 7.4 buffers, due to the presence of enzymes. However, in our case, we did not make
such an assumption because of two reasons. First, proteases responsible for degradation of
similar peptide linkers of other prodrugs are shown to be present in tissue lysosomes with an
optimal pH of ~4.16 Furthermore, previous works on dextran-methylprednisolone succinate
conjugates9,10 showed that esterases in blood could not release MP from its dextran conjugate.
Therefore, we anticipated similar degradation kinetics in the pH 7.4 buffer and blood for our
newly-synthesized conjugates. Although the degradation half life values of the conjugates with
mGG, mGGGG, and mGGGGG were similar in the pH 7.4 buffer and blood, those of the
conjugates with mG and mGGG linkers showed longer half lives in blood (Table 3). The
mechanisms responsible for the apparent increased stability of MPS-mG-Dex and MPS-
mGGG-Dex in blood are not known, although minor differences in the actual pH of the two
media during the experiments may have been a contributing factor. Nevertheless, similar to
the degradation data in the pH 7.4 buffer, the degradation of the conjugates in blood was
affected by the length of the linker (Fig. 4). Overall, hydrolysis kinetics of most of the studied
DMP conjugates in blood (Table 3) are slow enough to allow substantial hepatic accumulation
of the intact conjugates after their in vivo administration.
It is generally believed that dextran conjugates enter cells via endocytosis, ultimately arriving
in the lysosomal compartment of the cell.26,27 Therefore, it is necessary to study the fate of
dextran conjugates in the presence of lysosomal enzymes. In vitro incubation of the conjugates
with a crude lysosomal fraction obtained from rats resulted in degradation of the conjugate,
releasing all the possible intermediates (Fig. 7). The dependency of the release rate on the
length of the peptide, observed in our studies (Fig. 7f), is in agreement with previous
studies14–16,28 using peptides as linkers for conjugation of macromolecular carriers to drugs,
such as anticancer agents. For example, Harada et al.16 attached T-0128, a camptothecin
analogue, to carboxymethyl-dextran using peptides with various peptide linkers. In agreement
with the results presented here (Fig. 7), these authors showed that both in vitro release in the
presence of lysosomal fractions and in vivo release in tumors and livers of tumor-bearing rats
increased with lengthening the Gly chain. Therefore, using the conjugates developed in our
studies containing different lengths of Gly-chain linker, the rate of release of MP in vivo may
be controlled and an optimum linker selected in future in vivo studies.
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To determine the mechanism(s) of hydrolysis of peptidic bonds in lysosomes, further studies
were carried out using individual peptidases. In addition to lysosomal proteinases (cathepsin
B, cathepsin D, and trypsin), we also included papain in our studies because a number of
lysosomal cathepsins in humans and animals are cysteine peptidases that belong to the papain
family.29,30 Relatively significant hydrolysis of the peptide linkers by papain (Fig. 5) and
cathepsin B (Fig. 6) and lack of hydrolysis by cathepsin D or trypsin (data not shown) strongly
suggest enzymatic hydrolysis of the linkers by cysteine (papain and cathepsin B) proteinases.
This is in agreement with the report of Harada et al.,16 who demonstrated a significant role
for cathepsin B in the release of a camptothecin analogue from a conjugate with Gly-Gly-Gly
linker.
Our previous study31 clearly showed that MP attached to dextran macromolecule via a
succinate linker is not effective by itself and has to release MP in order to be effective. In our
current studies with new conjugates containing peptide linkers, hydrolysis of the conjugates
in different media resulted in the generation of both free MP and its peptidyl derivatives (Figs.
3, 5, 6, and 7). Whether peptidyl derivatives are effective by themselves or need to release MP
to be effective has not been studied. However, considering the interaction of most ligands with
their receptors, it is unlikely that the intact MPS-peptidyl derivatives can react with the
cytosolic glucocorticoid receptors. Nevertheless, additional investigations are needed to study
the effectiveness, if any, of MPS-peptidyl derivatives.
In conclusion, dextran prodrugs of methylprednisolone with peptide linkers containing one to
five Gly moieties were synthesized. A reversed-phase HPLC method was developed and
validated to quantitate all seven possible hydrolysis products of the conjugates. The in vitro
hydrolytic patterns of DMP conjugates to MP and MPS-peptidyl intermediates were
determined in buffers, blood, liver lysosomes, and in the presence of various peptidases. The
conjugates were relatively stable in rat blood. However, they generated all the possible
intermediates in the presence of liver lysosomes, with the rate of release increasing with an
increase in the length of the peptide linker. Among studied lysosomal enzymes, cysteine
peptidases, such as cathepsin B, appear to play a major role in the hydrolysis of these conjugates
in the lysosomes. The results of this study indicate that the dextran-peptide-methylprednisolone
conjugates may be of interest for therapeutic lysomotropic delivery of MP. Future studies are
underway to investigate the in vivo behavior of these conjugates.
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Figure 1.
Chromatograms of a blank deactivated lysosomal sample (top), a standard deactivated
lysosomal sample containing 5 μg/mL of MP, MPS, MPS-mG-OH, MPS-mGG-OH, MPS-
mGGG-OH, MPS-mGGGG-OH, and MPS-mGGGGG-OH (middle), and a sample taken 48 h
after incubation (37°C) of 100 μg/mL (MP equivalent) MPS-mGGGGG-Dex with active
lysosomes (bottom).
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Figure 2.
Concentration-time courses of DMP conjugates with five different linkers after incubation (37°
C) in pH 7.4 buffer. Symbols and bars represent mean and standard deviations, respectively.
Lines represent first-order fits to the data (n = 3).
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Figure 3.
A–E: In vitro release profiles of MP and MPS-peptidyl intermediates after incubation (37°C)
of DMP conjugates with five different linkers in pH 7.4 buffer. F: Total MP equivalent released
at 12 h versus the number of amino acids in the linker. Symbols and bars represent mean and
standard deviations, respectively (n = 3).
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Figure 4.
Concentration-time courses of DMP conjugates with five different linkers after incubation (37°
C) in rat blood. Symbols and bars represent mean and standard deviations, respectively. Lines
represent first-order fits to the data (n = 3).
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Figure 5.
A–E: In vitro release profiles of MP and MPS-peptidyl intermediates after incubation (37°C)
of DMP conjugates with five different linkers in the presence of papain. F: Total MP equivalent
released at 48 h versus the number of amino acids in the linker. Symbols and bars represent
mean and standard deviations, respectively (n = 3).
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Figure 6.
A–E: In vitro release profiles of MP and MPS-peptidyl intermediates after incubation (37°C)
of DMP conjugates with five different linkers in the presence of cathepsin-B. F: Total MP
equivalent released at 48 h versus the number of amino acids in the linker. Symbols and bars
represent mean and standard deviations, respectively (n = 3).
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Figure 7.
A–E: In vitro release profiles of MP and MPS-peptidyl intermediates after incubation (37°C)
of DMP conjugates with five different linkers in the presence of rat lysosomal fraction. F: Total
MP equivalent released at 48 h versus the number of amino acids in the linker. Symbols and
bars represent mean and standard deviations, respectively (n = 3).
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Scheme 1.
Synthesis of MPS-mGGGGG-OH and MPS-mGGGGG-dextran. Reagents: (i) Piperidine
(20%), DMF, (ii) Fmoc-Gly-OH, HBTU, DMF, (iii) Fmoc-mGly-OH, HBTU, DMF, (iv) MPS,
HBTU.
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Table 1
Average ± SD values (%) of degree of substitution (DS) and purity of the MPS-peptide-dextran conjugates (n = 3).
Conjugate DS (%) Purity (%)
MPS-mG-Dex 9.4 ± 0.2 91
MPS-mGG-Dex 7.0 ± 0.2 91
MPS-mGGG-Dex 9.5 ± 0.9 95
MPS-mGGGG-Dex 7.4 ± 0.1 90
MPS-mGGGGG-Dex 6.9 ± 0.1 93
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Table 2
Inter-run accuracy (%Error) and precision (%CV) of the reversed-phase assay (n =5)
Analyte Added Conc. (μg/mL) Calculated Conc. (μg/mL) % Error % CV
MP 0.5 0.50 0.5 6.3
MPS 0.5 0.49 −2.9 3.1
MPS-mG-OH 0.5 0.53 6.9 5.5
MPS-mGG-OH 0.5 0.48 −3.6 3.5
MPS-mGGG-OH 0.5 0.48 −4.7 8.7
MPS-mGGGG-OH 0.5 0.44 −12.8 12.0
MPS-mGGGGG-OH 0.5 0.43 −13.2 9.8
MP 5 5.06 1.1 1.2
MPS 5 4.82 −3.6 2.4
MPS-mG-OH 5 4.79 −4.2 1.6
MPS-mGG-OH 5 4.81 −3.8 1.0
MPS-mGGG-OH 5 4.82 −3.6 2.2
MPS-mGGGG-OH 5 4.82 −3.6 0.7
MPS-mGGGGG-OH 5 4.87 −2.6 1.3
MP 100 108 7.6 1.6
MPS 100 107 7.2 1.7
MPS-mG-OH 100 108 7.7 3.2
MPS-mGG-OH 100 104 3.9 3.1
MPS-mGGG-OH 100 103 3.2 3.2
MPS-mGGGG-OH 100 102 2.0 2.8
MPS-mGGGGG-OH 100 101 0.6 3.5
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Table 3
Mean ± SD values of degradation half lives (h) of DMP conjugates in pH 7.4 buffer and rat blood (n = 3).
pH 7.4 Blood
MPS-mG-Dex 10.7 ± 0.1a,b,c,d,e 24.5 ± 3.0e,g,h,i
MPS-mGG-Dex 5.67 ± 0.03a 8.36 ± 0.45g
MPS-mGGG-Dex 5.87 ± 0.03b,f 9.80 ± 0.25f,h,j
MPS-mGGGG-Dex 4.69 ± 0.03c 6.89 ± 0.25i
MPS-mGGGGG-Dex 4.27 ± 0.02d 4.67 ± 0.21g,j
a–j
Means with similar letters are significantly different each other: ANOVA with post-hoc Scheffe test..
J Pharm Sci. Author manuscript; available in PMC 2008 July 1.
